SLC5A2 and diabetes mellitus: A further reduction of 24-h systolic BP (about 8 mmHg) was also observed in treated diabetic and hypertensive patients after adding empagliflozin in the SGLT2 inhibitor and Angiotensin Receptor Blocker Combination Therapy in Patients With Diabetes and Uncontrolled Nocturnal Hypertension study [31].